A Dose of Life

A Profile On

Ipca Laboratories Ltd.

Based on Marketing Perspective

THE BRAND LOGO(It’s Transformation through the time)

•Butterfly represents “LIFE at its energetic best”•Molecule in between represents “ Pharmaceutical bent of the Company”•Flight of the butterfly represents “soaring aspirations of the company” and• BLUE color represents “ Health, Healing, Wisdom and Confidence.

ABOUT THE COMPANY•A Public Ltd. Company

•Founded in 1949 by K.B. Mehta and N.S. Tibrawala in Mumbai (INDIA)

•Headquarters situated at Mumbai

•Current Management Team: Mr. Prem Chandra Godha (Managing Director)

Mr. A.K.Jain (Joint Managing Director)

•Areas served is worldwide

•Products Manufactured: Pharmaceuticals and Drugs

•Business Model: Fully integrated Pharmaceutical company mfg. branded and generic formulations, active pharmaceutical ingredients and intermediates

•Total income in the F.Y. 2012-13: Rs. 2797.08 Crores

•Total exports in F.Y. 2012-13: Rs.1716.08 Crores

•Manufacturing Facilities: Pithampur (Madhya Pradesh) Athal (Gujrat) Dehradun (Uttarakhand) Kandla (Gujrat) Ratlam (Madhya Pradesh) Indore (Madhya Pradesh) Ankaleshwar (Gujrat) Mahad (Maharashtra)

•International Presence: U.S.A., U.K., Australia, New Zealand, Nigeria and China•Marketing Offices (Abroad): Kenya, Philippines, Vietnam, Columbia, Peru, Malaysia, Sri Lanka

•Major Subsidiaries: CCPL Soft wares(For Patient Counseling) PADAAV (IPCA Traditional Remedy Center for Ayurvedic Treatment)

•At one time the control of the company was held by THE BACHCHANS in 1975

PRODUCTS MANUFACTURED BY THE COMPANY

A.

P.I’s

AtenelolChloroquineFurosemideMetoprolol SuccinatePyrantel Salts

BRANDED FORMULATI

ONS

ZerodolLariagoPerinormRapitherLumeraxEtovaFolitrax

BRANDED GENERI

CS

Oral SolidsOral LiquidsDry Powders Suspension PowdersDry InjectablesLiquid Injectables

Ipca is the largest mfr. of anti malarial drugs in INDIA

TOP FORMULATION BRANDS OF IPCA LABS

1.ZERODOL(Analgesics)2.LARIAGO(Anti-

malarial)3.HYDROXYCHLOROQUI

NE4.PERINORM(anti-

emetic)5.RAPITHER (Anti-

malarial)

6. TENORIC (Beta Blockers)7. LUMERAX (Anti-malarials)8. ETOVA (Anti-inflammatory)9. FOLITRAX (Anti-cancer)

MARKETTING DIVISIONS OF THE COMPANY

Deals with Cardio-diabetic disorders

Deals with cardio diabetic disorders and lipid management

Deals with rheumatologic and orthopedic disorders

Deals with surgical and non surgical equipments

Deals with dermatological disorders

Deals with first line treatment of patients

Cardiologists Neuropsychiatry

Orthopedics

Anti- Malarial Multi specialty areas

MAJOR COMPETITORS IN THE MARKET

NATCO PHARMACEUTICALS LTD.

MERCK INDUSTRIES LTD.

UNICHEM LABORATORIES LTD.

PLETHICO PHARMACEUTICALS LTD.

MARKET STRATEGY OF THE COMPANY

•Major focus on high value products and reduction in dependence on low value generic products.

•Entry of the company in the U.S. markets through tie ups with RANBAXY and HARIATGE Pharma

•Aggressive ANDA (Abbreviated New Drug Application) in the U.S. Markets.

•Maintaining Therapy focused marketing divisions.

•In house clinical research facilities and focusing on the safety and well being of the of the patient.

•Exports in over 120 countries across the globe and marketing offices in every major continent.

•Continuous introduction of new products in domestic and international markets.

SWOT ANALYSIS

STRENGTHS

•Worldwide presence in anti malarial market capturing almost 1/3rd of the market.

•Large network of wholesalers and sales and marketing executives.

•Strong and stable financial position of the company.

•Dosage forms against all malarial disorders.

•Major attention on formulation segment.

•Presence in international market.

WEAKNESS

•Focus on brand building and promotional activities is less.

•Limited and slow market share growth.

OPPORTUNITIES

•Increasing demand for therapeutic drugs in the Indian and Chinese market.

•Acquisition of more and more research based firms will help increase the therapeutic product range to a great extent.

•Expansion in the therapeutic segment in Nutraceutical, nephrology and urology will improve profits.

THREATS

•Reduced funds and infrastructure facilities for public healthcare

•Depreciating value of currency poses a threat to the research driven activities

•Global economic slowdown

CHANNEL OF DISTRIBUTION OF THE PRODUCTS

MODEL “A” MODEL “B”

CORPORATE SOCIAL RESPONSIBILITIES OF THE COMPANY

CSR ACTIVITIES-AREAS OF

OPERATION

Health Education

and Awareness

Environment

Management Systems

Health and Safety

Employees and Society Developmen

t

PRODUCT LINE, LENGTH AND MIX

PROMOTIONAL ADVERTISEMENT (Based on U.S.P.)